Đang chuẩn bị liên kết để tải về tài liệu:
Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

To compare the efficacy of crizotinib, pemetrexed and other chemotherapy regimens as a first-line treatment in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in real world clinical use and to evaluate the +86–571-87,236,876 predictive clinical factors of the efficacy of crizotinib. | Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

TÀI LIỆU LIÊN QUAN

A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: A case report

The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: A meta-analysis of clinical trials

Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

A retrospective study of alectinib versus ceritinib in patients with advanced non– small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Alteration in the sensitivity to crizotinib by Na+ /H+ exchanger regulatory factor 1 is dependent to its subcellular localization in ALK-positive lung cancers

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: A case report and literature review

Post-crizotinib management of effective ceritinib therapy in a patient with ALKpositive non-small cell lung cancer

Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma

Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: A case report